- Home
- KF vs TNYA Comparison
KF vs TNYA Comparison
Compare KF & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- TNYA
- Stock Information
- Founded
- KF 1984
- TNYA 2016
- Country
- KF United States
- TNYA United States
- Employees
- KF N/A
- TNYA N/A
- Industry
- KF Investment Managers
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- KF Finance
- TNYA Health Care
- Exchange
- KF Nasdaq
- TNYA Nasdaq
- Market Cap
- KF 116.7M
- TNYA 111.1M
- IPO Year
- KF N/A
- TNYA 2021
- Fundamental
- Price
- KF $27.87
- TNYA $1.16
- Analyst Decision
- KF
- TNYA Strong Buy
- Analyst Count
- KF 0
- TNYA 5
- Target Price
- KF N/A
- TNYA $8.60
- AVG Volume (30 Days)
- KF 18.4K
- TNYA 2.5M
- Earning Date
- KF 01-01-0001
- TNYA 08-06-2025
- Dividend Yield
- KF N/A
- TNYA N/A
- EPS Growth
- KF N/A
- TNYA N/A
- EPS
- KF N/A
- TNYA N/A
- Revenue
- KF N/A
- TNYA N/A
- Revenue This Year
- KF N/A
- TNYA N/A
- Revenue Next Year
- KF N/A
- TNYA N/A
- P/E Ratio
- KF N/A
- TNYA N/A
- Revenue Growth
- KF N/A
- TNYA N/A
- 52 Week Low
- KF $18.30
- TNYA $0.36
- 52 Week High
- KF $25.56
- TNYA $4.01
- Technical
- Relative Strength Index (RSI)
- KF 55.47
- TNYA 80.21
- Support Level
- KF $27.58
- TNYA $0.65
- Resistance Level
- KF $28.49
- TNYA $0.72
- Average True Range (ATR)
- KF 0.30
- TNYA 0.08
- MACD
- KF -0.04
- TNYA 0.03
- Stochastic Oscillator
- KF 65.97
- TNYA 100.00
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.